Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites

与领先的生物技术公司合作，招募了28%的研究参与者，与传统的实体临床试验地点相比，招募速度提高了22倍

RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

RESEARCH TRIANGLE PARK，N.C.，2024年5月2日（Global NEWSWIRE）--Science 37 Holdings，Inc.今天披露了其与一家领先的生物技术公司的Metasite™和患者招募合作关系产生的最新登记数字，该公司的哮喘药物目前正在进行3期临床试验。

Leveraging its proprietary Metasite™ and Patient Recruitment solutions, Science 37 contributed 28% of all randomized study participants over a 15-month enrollment window. Science 37 averaged 44 patients enrolled per month, while each of the 55 brick-and-mortar sites supporting the trial enrolled an average of two participants per month.

利用其专有的Metasite™和患者招募解决方案，Science 37在15个月的注册窗口内贡献了所有随机研究参与者的28%。Science 37平均每月招募44名患者，而支持该试验的55个实体网站平均每月招募两名参与者。

Science 37 delivered an enrollment velocity 22x greater than study sites in the trial and reduced the study’s overall time-to-target enrollment..

Science 37的注册速度比试验中的研究地点高22倍，并缩短了研究的总体目标注册时间。。

“When a study sponsor entrusts us to fully accelerate its clinical research, our role becomes twofold,” said Dr. Lianne Marks, Medical Director and Primary Investigator at Science 37. “The first is to improve upon the traditional patient recruitment model using the built-in outreach, screening, and medical consent advantages of our recruitment solution.

“当一个研究赞助商委托我们全面加速其临床研究时，我们的角色就变成了双重的，”科学37的医学主任和主要研究者Lianne Marks博士说。“首先是利用我们招聘解决方案的内置外联、筛查和医疗同意优势，改进传统的患者招聘模式。

The second is to further enhance study conduct through our Metasite by expanding participant access to the 90+ percent patient population that is unreachable in brick-and-mortar research,” she added..

第二个是通过我们的Metasite进一步加强研究行为，通过扩大参与者对90%以上的患者人群的访问，这在实体研究中是无法实现的，”她补充道。。

Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated research offering. For more information, please visit www.science37.com..

Science 37的患者招募可以单独提供给临床研究赞助商和CRO，以加强他们的患者招募工作，或者与Science 37业界领先的旗舰虚拟网站Metasite™结合，作为加速研究服务的一部分。有关更多信息，请访问www.science37.com。。

About Science 37

关于科学37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site.

Science 37的使命是通过为患者提供普遍的试验机会来加速临床研究。通过我们的解决方案；在Metasite™和患者招募方面，我们通过将临床试验的范围扩大到传统站点之外的患者，并在将患者转诊到传统站点之前对其进行严格的资格鉴定，从而加速了注册。

Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com..

我们的解决方案由内部医疗和运营专家的专有技术支持，通过标准化的工作流程和一流的研究编排来提高质量。要了解更多信息，请访问www.science37.com或电子邮件science37@science37.com..

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies/.

要查看Science 37正在积极招募的研究，请访问https://studies.science37.com/current-studies/.

Media Inquiries

媒体查询

Science 37

科学37

PR@science37.com

PR@science37.com